Testing for Biotin Interference in In Vitro Diagnostic Devices

On 15 October 2020 the FDA announced the availability of the final guidance for industry.

FDA is providing recommendations on the testing for interference by biotin on the performance of in vitro diagnostic devices (IVDs). This guidance is intended to help device developers and clinicians understand how FDA recommends biotin interference testing be performed, and how the results of the testing should be communicated to end-users, including clinical laboratories and clinicians. The recommendations apply to IVDs, including devices that are licensed under section 351 of the Public Health Service Act (42 U.S.C. 262) and used in donor screening, that use biotin technology. This guidance finalizes the draft guidance of the same title dated June 2019.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /